US EditionUniversal vaccine for cold, flu, COVID and allergies 'moves a step closer'
The nasal spray vaccine protected mice for months against viruses, bacteria, and allergens, potentially replacing multiple annual shots, researchers said.
- Researchers at Stanford Medicine published findings today showing a nasal‑spray vaccine, GLA-3M-052-LS+OVA, protected mice against diverse respiratory viruses, bacteria and allergens for at least three months.
- By design, the vaccine mimics T‑cell signals to stimulate the innate immune system and recruit T cells in the lungs, a radical departure from conventional vaccines used for more than 200 years.
- In lab tests, mice given four doses experienced a 100-to-1,000-fold reduction in viral entry and protection against Staphylococcus aureus, Acinetobacter baumannii, and house dust mites.
- The team plans human trials that would start with a safety trial followed by a deliberate-exposure trial, estimating availability in five to seven years if funded, though effects in people remain unknown.
- Experts hailed the work as promising yet cautioned that if translated to humans, the vaccine could replace multiple annual respiratory shots and offer a pandemic first‑line defence, though immune overactivation risks remain.
14 Articles
14 Articles
Sky News UK
Great Yorkshire RadioUniversal vaccine for cold, flu, COVID and allergies moves a step closer, scientists say
A universal vaccine for humans against cold, flu, COVID and allergies has moved a significant step closer following a study using mice, scientists say.
‘Universal vaccine’ protects mice against multiple pathogens
An innovative approach supercharges the innate immune system to provide a first line of defence against respiratory infections. An innovative approach supercharges the innate immune system to provide a first line of defence against respiratory infections.
Scientists hail breakthrough in quest for universal vaccine
A nasal spray vaccine protecting against colds, flu, Covid and allergies could be within reach after promising early-stage laboratory results in mice. There is rarely a time of year free from respiratory illness. Winter brings colds and flu, while spring and simmer usher in hay fever. Now, researchers at Stanford Medicine say a new vaccine formula could be a significant step towards longer-lasting protection. The vaccine, delivered via a nasal …
Coverage Details
Bias Distribution
- 67% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
